These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 3392741)
21. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. Rowinsky EK; Humphrey R; Hammond LA; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen JM; Von Hoff DD; Eckhardt SG J Clin Oncol; 2000 Jan; 18(1):178-86. PubMed ID: 10623708 [TBL] [Abstract][Full Text] [Related]
22. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Goldsmith MA; Slavik M; Carter SK Cancer Res; 1975 May; 35(5):1354-64. PubMed ID: 804350 [TBL] [Abstract][Full Text] [Related]
23. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929 [TBL] [Abstract][Full Text] [Related]
24. Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. Spector NL; Robertson FC; Bacus S; Blackwell K; Smith DA; Glenn K; Cartee L; Harris J; Kimbrough CL; Gittelman M; Avisar E; Beitsch P; Koch KM PLoS One; 2015; 10(11):e0142845. PubMed ID: 26571496 [TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan). Giovanella BC; Stehlin JS; Hinz HR; Kozielski AJ; Harris NJ; Vardeman DM Int J Oncol; 2002 Jan; 20(1):81-8. PubMed ID: 11743646 [TBL] [Abstract][Full Text] [Related]
26. Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine. Reichelová V; Juliusson G; Spasokoukotskaja T; Eriksson S; Liliemark J Cancer Chemother Pharmacol; 1995; 36(6):524-9. PubMed ID: 7554045 [TBL] [Abstract][Full Text] [Related]
27. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017 [TBL] [Abstract][Full Text] [Related]
28. Methodological aspects of the 6-day subrenal capsule assay for measuring the response of human tumors to anticancer agents. Aamdal S; Fodstad O; Pihl A Anticancer Res; 1985; 5(4):329-37. PubMed ID: 4037730 [TBL] [Abstract][Full Text] [Related]
29. Relation of preclinical toxicology to findings in early clinical trials. Grieshaber CK; Marsoni S Cancer Treat Rep; 1986 Jan; 70(1):65-72. PubMed ID: 3943115 [TBL] [Abstract][Full Text] [Related]
30. Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice. Chouchou A; Marion B; Enjalbal C; Roques C; Cuq P; Bonnet PA; Bressolle-Gomeni FMM; Deleuze-Masquéfa C J Pharm Biomed Anal; 2018 Jan; 148():369-379. PubMed ID: 29111492 [TBL] [Abstract][Full Text] [Related]
31. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Pourpak A; Meyers RO; Samulitis BK; Sherry Chow HH; Kepler CY; Raymond MA; Hersh E; Dorr RT Anticancer Drugs; 2006 Nov; 17(10):1179-84. PubMed ID: 17075317 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo. Dell'Erba C; Chiavarina B; Fenoglio C; Petrillo G; Cordazzo C; Boncompagni E; Spinelli D; Ognio E; Aiello C; Mariggiò MA; Viale M Pharmacol Res; 2005 Sep; 52(3):271-82. PubMed ID: 15921920 [TBL] [Abstract][Full Text] [Related]
33. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Kratz F; Ehling G; Kauffmann HM; Unger C Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177 [TBL] [Abstract][Full Text] [Related]
34. New screening system for selection of anticancer drugs for treatment of human colorectal cancer. Scheithauer W; Clark GM; Moyer MP; Von Hoff DD Cancer Res; 1986 Jun; 46(6):2703-8. PubMed ID: 3698003 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1. Foster BJ; Wiegand RA; LoRusso PM; Baker LH Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052 [TBL] [Abstract][Full Text] [Related]
36. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439 [TBL] [Abstract][Full Text] [Related]
37. Effect of thymidine on the toxicity and antitumor activity of ftorafur. Grossie VB; Loo TL Cancer Treat Rep; 1981; 65(11-12):1087-91. PubMed ID: 6794908 [TBL] [Abstract][Full Text] [Related]
38. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide. Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053 [TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. O'Leary JJ; Shapiro RL; Ren CJ; Chuang N; Cohen HW; Potmesil M Clin Cancer Res; 1999 Jan; 5(1):181-7. PubMed ID: 9918217 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity. Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]